Q (sonnet): For patients with the EML4-ALK fusion gene in lung cancer how do the different fusion variants affect their long-term quality of life and risk of developing a secondary cancer?

═ answer (success)
I need to flag some important limitations before addressing this question.

**cBioPortal does not contain the data needed to answer this as asked.** Specifically:

1. **Quality of life** is not a data type captured in cBioPortal. The database holds genomic alterations (mutations, fusions, copy number), and clinical/demographic attributes (survival time, stage, treatment, etc.) as recorded per study — it does not include patient-reported outcomes, quality-of-life instruments (e.g., EORTC QLQ-C30), or similar measures.

2. **Risk of developing a secondary cancer** is not tracked either. Some studies include a "new tumor event" or subsequent malignancy field if the contributing study happened to collect it, but this is not systematically available across studies, and cBioPortal is not designed to support causal inference about secondary cancer risk by fusion variant.

3. **EML4-ALK fusion variants** (e.g., variant 1/E13;A20, variant 3a/b/E6;A20, etc.) are distinguished by specific intron/exon breakpoints. cBioPortal's structural variant / fusion data generally records the fusion gene pair (EML4-ALK) but often does not resolve the exact breakpoint-level "variant" subtype in a consistent, queryable way across studies — this level of granularity is typically only in specialized ALK-fusion literature, not in cBioPortal's structured tables.

Given these three gaps, I can't responsibly produce numbers or trends for "how variant X affects long-term QOL or secondary cancer risk" — that would require fabricating data cBioPortal doesn't have, which I won't do.

### What I *can* do from cBioPortal
- Identify lung cancer cohorts with ALK fusions and show which patients/samples harbor EML4-ALK (via the Structural Variants / fusion data or OncoPrint).
- Report on real clinical fields that do exist in these studies (overall survival, disease-free survival, stage, smoking status, treatment) split by ALK-fusion status — using proper Kaplan-Meier survival comparisons via the Group Comparison tool rather than a fabricated median.
- Check specific studies' Structural Variant tables to see if breakpoint-level variant annotation happens to be present (some targeted NSCLC studies with SV calling might have this) — but I'd need to search per-study rather than promise it in general.

Would you like me to:
1. Pull up lung cancer studies with ALK fusion/structural variant data and show you overall survival by ALK-fusion status (a legitimate genomic-outcome comparison), and/or
2. Search a specific study (e.g., a targeted ALK-inhibitor trial cohort) to see if it happens to annotate EML4-ALK breakpoint variants?

For quality-of-life and secondary-malignancy risk specifically, you'd need a source designed for that — e.g., published ALK-TKI clinical trial follow-up studies (ALEX, PROFILE trials) or PRO registries, which are outside what I can query here.